CytoSorbents Corporation (CTSO)
| Market Cap | 258.70M |
| Revenue (ttm) | 45.13M |
| Net Income (ttm) | -10.36M |
| Shares Out | 43.32M |
| EPS (ttm) | -0.24 |
| PE Ratio | n/a |
| Forward PE | 106.38 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 208,148 |
| Open | 6.01 |
| Previous Close | 6.04 |
| Day's Range | 5.79 - 6.02 |
| 52-Week Range | 5.79 - 11.68 |
| Beta | 0.41 |
| Analysts | Strong Buy |
| Price Target | 12.67 (+117.3%) |
| Est. Earnings Date | Nov 4, 2021 |
About CTSO
Cytosorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention and treatment of post-operative complications of cardiopulmonary bypass surgery, and maintainin...
Financial Performance
In 2020, CytoSorbents's revenue was $41.00 million, an increase of 64.35% compared to the previous year's $24.95 million. Losses were -$7.84 million, -59.32% less than in 2019.
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for CytoSorbents stock is "Strong Buy." The 12-month stock price forecast is 12.67, which is an increase of 117.32% from the latest price.
News
CytoSorbents Comments on REMOVE Study Presentation
MONMOUTH JUNCTION, N.J., Oct. 20, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using CytoS...
First Patient Enrolled in U.S. STAR-T Pivotal Trial Evaluating the DrugSorb-ATR™ Antithrombotic Removal System to Rem...
MONMOUTH JUNCTION, N.J., Oct. 14, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blo...
CytoSorbents Receives Full FDA Investigational Device Exemption (IDE) Approval to Begin U.S. STAR-D Trial on Apixaban...
MONMOUTH JUNCTION, N.J., Oct. 12, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood...
CytoSorbents Provides Preliminary Third Quarter Business Update and Revised 2021 Product Revenue Guidance
MONMOUTH JUNCTION, N.J., Oct. 12, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blo...
CytoSorbents Announces Availability of Preliminary Data Abstracts from Two Endocarditis Studies, including the REMOVE...
MONMOUTH JUNCTION, N.J., Oct. 7, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using bloo...
CytoSorbents to Host International Webinar on the Worldwide Experience Using CytoSorb® in Critically Ill Patients wit...
MONMOUTH JUNCTION, N.J., Sept. 14, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery announce...
A Trio of Stocks Growing Revenue Per Share Fast
The S&P 500 stocks saw their aggregate trailing 12-month real revenue per share grow at a compound annual growth rate of approximately 2.4% over the past five years. The share price of the benchmark ind...
CytoSorbents Commemorates World Sepsis Day and Sepsis Awareness Month with Key Sepsis-Related Events, Sponsorships an...
MONMOUTH JUNCTION, N.J., Sept. 13, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions, such as sepsis, in intensive care and cardiac...
CytoSorbents Announces Filing of an Investigational Device Exemption (IDE) for the U.S. Clinical Trial on Apixaban an...
MONMOUTH JUNCTION, N.J., Sept. 10, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using bl...
CytoSorbents Announces Webinar Discussing Topline Results from the U.S. CTC Registry using CytoSorb® in Critically Il...
MONMOUTH JUNCTION, N.J., Sept. 8, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blo...
CytoSorbents' Product Associated With High Survival In Critically Ill COVID-19 Patients
CytoSorbents Corporation (NASDAQ: CTSO) has announced topline results from its CytoSorb Therapy in COVID-19 (CTC) multicenter registry. The data were presented at the International Symposium on Intensiv...
Topline Results from CytoSorbents' U.S. CTC Multicenter Registry Demonstrate High Survival using CytoSorb® in Critica...
MONMOUTH JUNCTION, N.J., Sept. 1, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood...
CytoSorbents, Aferetica Launch Organ Perfusion System In Italy
CytoSorbents Corporation (NASDAQ: CTSO) and Aferetica srl (Italy) have launched products to remove inflammatory mediators at Italy's European Society of Organ Transplantation Congress. Aferetica's PerLi...
CytoSorbents and Aferetica Announce the Commercial Launch in Italy of the PerSorb™ Adsorber and PerLife™ Organ Perfus...
MONMOUTH JUNCTION, N.J. and BOLOGNA, Italy, Aug. 30, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO) and Aferetica srl (Italy), two pioneers in intensive care immunotherapy and blood purifi...
CytoSorbents' Antithrombotic Removal System Scores Second FDA Breakthrough Device Tag
The FDA has granted a second Breakthrough Device designation to CytoSorbents Corporation's (NASDAQ: CTSO) DrugSorb-ATR Antithrombotic Removal System. The designation covers removing the Direct Oral An...
Second U.S. FDA Breakthrough Device Designation Granted to CytoSorbents' DrugSorb-ATR™ Antithrombotic Removal System ...
MONMOUTH JUNCTION, N.J., Aug. 12, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blo...
CytoSorbents Q2 Earnings Lag Consensus, Higher Costs Weigh On Bottom Line
CytoSorbents Corporation (NASDAQ: CTSO) reported Q2 revenue of $12 million, up 23% Y/Y, but missing the consensus of $12.27 million. Product sales increased 19% Y/Y to $11.4 million.
CytoSorbents Reports Second Quarter 2021 Financial and Operational Results
MONMOUTH JUNCTION, N.J., Aug. 3, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using bloo...
CytoSorbents Completes its Mission 100,000 International Fundraising Campaign to Fight the Spread of COVID-19 for Glo...
MONMOUTH JUNCTION, N.J., July 30, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood...
CytoSorbents to Report Second Quarter 2021 Operating and Financial Results
MONMOUTH JUNCTION, N.J., July 19, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO) a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery usi...
Here's Why Cytosorbents Is Up 17% Today
The biotech company took another step toward introducing a new way of performing bypass surgeries.
CytoSorbents Shares Are Trading Higher On Launch Of Trial On Ticagrelor Removal During Cardiothoracic Surgery
CytoSorbents Corporation (NASDAQ: CTSO) receives full FDA approval to conduct the STAR-T trial in the U.S. to support regulatory clearance of DrugSorb Antithrombotic Removal (ATR) system for intraoperat...
CytoSorbents Receives Full FDA Approval of Investigational Device Exemption (IDE) for U.S. STAR-T Trial on Ticagrelor...
MONMOUTH JUNCTION, N.J., July 6, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO) announces the full approval of its Investigational Device Exemption (IDE) application to conduct the pivotal...
CytoSorbents Appoints Terri Anne Powers, IRC as Vice President of Investor Relations and Corporate Communications
MONMOUTH JUNCTION, N.J., June 1, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care therapy leader commercializing its CytoSorb® blood purification technology to treat deadly ...
CytoSorbents to Present at the Jefferies Virtual Healthcare Conference
MONMOUTH JUNCTION, N.J., May 27, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care leader commercializing its CytoSorb® blood purification technology to treat deadly conditio...